A Comparison of LY2605541 Versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naive Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With 2 or More Oral Antihyperglycemic Medications: An Open-Label, Randomized Study

Trial Profile

A Comparison of LY2605541 Versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naive Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With 2 or More Oral Antihyperglycemic Medications: An Open-Label, Randomized Study

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Insulin peglispro (Primary) ; Insulin suspension isophane (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms IMAGINE-6
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2015 Results (pooled analysis of IMAGINE 1, 2, 3, 4, 5 and 6 trials) presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top